Synlab has collaborated with genomic and theranostic firm OncoDNA to offer the OncoDeep biomarker test for cancer therapy selection in Germany.

As part of the collaboration, Synlab Laboratories in Germany will have access to the OncoDeep test to perform comprehensive testing of solid tumours and provide support for oncologists.

The test is based on the analysis of more than 600 genes, as well as the measurement of genomic signatures, such as loss of heterozygosity (LOH), tumour mutational burden (TMB), homologous recombination deficiency (HRD) and microsatellite instability (MSI).

It was developed to determine whether a patient is eligible for targeted treatment or immunotherapy.

Synlab noted that immunohistochemistry (IHC) analyses will also be performed to measure protein expression and check patients’ eligibility for anti-cancer drugs.

The company’s laboratories in Mannheim and Jena will run the OncoDEEP test and operate the complete process, from test ordering to clinical recommendation reporting.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Synlab Germany human genetics, pathology and cytology head Dr Christian Mayer said: “OncoDeep is a real asset for oncology diagnostics offering in Germany.

“Particularly in comparison to a single biomarker test, the chance to comprehensively test and predict patient responses to a variety of treatments provides significant benefit to patients and doctors and ultimately delivers accurate decision support on the most effective treatment options.”

The transfer of the OncoDeep test technology to Synlab is ongoing, and processing of the first patient samples is expected early in the second quarter.

OncoDNA CEO Bernard Courtieu said: “Biomarker testing has the potential to improve patient outcomes and health quality. Improving access to these tests should be a priority worldwide. This collaboration will further support the uptake of precision medicine across Germany.”